Biotech Values

[mcbio]

Exelixis made a grave mistake, but the market’s reaction seems exaggerated and created a buying opportunity in my opinion.‹

What are your thoughts on this final point from Hammer? (FWIW, I tend to agree with him, or at least be much more open to EXEL than I was recently, given the large drop in valuation coupled with PoC for cabo in MTC.)